Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease

Background: Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is a risk factor for cardiovascular disease. The relationship between CHIP and coronary microvascular dysfunction (CMD) is unknown. The current study examines the association between CHIP and CH with CMD and the potential relationships in risk for adverse cardiovascular outcomes. Methods: In this retrospective observational study, targeted next-generation sequencing was performed for 177 participants with no coronary artery disease who presented with chest pain and underwent routine coronary functional angiogram. Patients with somatic mutations in leukemia-associated driver genes in hematopoietic stem and progenitor cells were examined; CHIP was considered at a variant allele fraction ≥2%; CH was considered at a variant allele fraction ≥1%. CMD was defined as coronary flow reserve to intracoronary adenosine of ≤2. Major adverse cardiovascular events considered were myocardial infarction, coronary revascularization, or stroke. Results: A total of 177 participants were examined. Mean follow-up was 12±7 years. A total of 17 patients had CHIP and 28 had CH. Cases with CMD (n=19) were compared with controls with no CMD (n=158). Cases were 56±9 years, were 68% women, and had more CHIP (27%; P=0.028) and CH (42%; P=0.001) than controls. CMD was associated with independent risk for major adverse cardiovascular events (hazard ratio, 3.89 [95% CI, 1.21–12.56]; P=0.023), and 32% of this risk was mediated by CH. The risk mediated by CH was ≈0.5× as large as the direct effect of CMD on major adverse cardiovascular events. Conclusions: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.

[1]  A. Jaffe,et al.  Plasma Ceramide Levels Are Elevated in Patients With Early Coronary Atherosclerosis and Endothelial Dysfunction , 2022, Journal of the American Heart Association.

[2]  Andrew D. Johnson,et al.  Clonal Hematopoiesis Is Associated With Higher Risk of Stroke , 2021, Stroke.

[3]  U. Wagner,et al.  Extracellular NLRP3 inflammasome particles are internalized by human coronary artery smooth muscle cells and induce pro-atherogenic effects , 2021, Scientific Reports.

[4]  P. Natarajan,et al.  Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. , 2021, Journal of molecular and cellular cardiology.

[5]  Yi Xie,et al.  TET2 Protects Against Vascular Smooth Muscle Cell Apoptosis and Intimal Thickening in Transplant Vasculopathy , 2021, Circulation.

[6]  A. Dopazo,et al.  Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction. , 2021, Journal of the American College of Cardiology.

[7]  L. Lerman,et al.  Coronary Microvascular Endothelial Dysfunction in Patients With Angina and Nonobstructive Coronary Artery Disease Is Associated With Elevated Serum Homocysteine Levels , 2020, Journal of the American Heart Association.

[8]  L. Lerman,et al.  Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction , 2020, European journal of heart failure.

[9]  G. Getz,et al.  Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant , 2020, Nature Communications.

[10]  V. Murthy,et al.  Association of Isolated Coronary Microvascular Dysfunction With Mortality and Major Adverse Cardiac Events: A Systematic Review and Meta‐Analysis of Aggregate Data , 2020, Journal of the American Heart Association.

[11]  S. Gabriel,et al.  Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis , 2019, Circulation.

[12]  P. Libby,et al.  Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease , 2019, Nature Reviews Cardiology.

[13]  R. Kwong,et al.  Global Coronary Flow Reserve Measured During Stress Cardiac Magnetic Resonance Imaging Is an Independent Predictor of Adverse Cardiovascular Events. , 2019, JACC. Cardiovascular imaging.

[14]  P. Libby,et al.  Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[15]  M. Price,et al.  The functional assessment of patients with non-obstructive coronary artery disease: expert review from an international microcirculation working group. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[16]  P. Libby,et al.  CHIPping Away at the Pathogenesis of Heart Failure. , 2019, JAMA cardiology.

[17]  B. Brüne,et al.  Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure , 2018, JAMA cardiology.

[18]  P. Libby,et al.  CHIP (Clonal Hematopoiesis of Indeterminate Potential). , 2018, Circulation.

[19]  Zuo Wang,et al.  TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis. , 2018, DNA and cell biology.

[20]  Fei Li,et al.  Clonal hematopoiesis of indeterminate potential (CHIP): A potential contributor to atherlosclerotic cardio/cerebro-vascular diseases? , 2018, Genes & diseases.

[21]  D. Goukassian,et al.  Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome. , 2018, Journal of the American College of Cardiology.

[22]  P. Libby,et al.  The Present and FutureReview Topic of the WeekInterleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond , 2017 .

[23]  S. Gabriel,et al.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.

[24]  Matthew A. Cooper,et al.  Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice , 2017, Science.

[25]  T. Druley,et al.  Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults , 2016, Nature Communications.

[26]  R Jay Widmer,et al.  Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery Disease. , 2015, JACC. Cardiovascular interventions.

[27]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[28]  Tetsuya Takahashi,et al.  Endothelial dysfunction is associated with the severity of cerebral small vessel disease , 2015, Hypertension Research.

[29]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[30]  Yu Jin,et al.  Ten-Eleven Translocation-2 (TET2) Is a Master Regulator of Smooth Muscle Cell Plasticity , 2013, Circulation.

[31]  J. Kaski,et al.  Coronary microvascular dysfunction in the clinical setting: from mystery to reality. , 2012, European heart journal.

[32]  Koki Nakanishi,et al.  Impaired coronary flow reserve as a marker of microvascular dysfunction to predict long-term cardiovascular outcomes, acute coronary syndrome and the development of heart failure. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[33]  M. Rubens,et al.  Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. , 2009, European heart journal.

[34]  F. Crea,et al.  Coronary microvascular dysfunction. , 2013, The New England journal of medicine.

[35]  A. Lerman,et al.  The endothelium: Dysfunction and beyond , 2001, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[36]  S. Higano,et al.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.

[37]  S. Higano,et al.  Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. , 1998, Mayo Clinic proceedings.